CA2654834A1 - Stimulation nerveuse dynamique employant une modulation de frequence - Google Patents

Stimulation nerveuse dynamique employant une modulation de frequence Download PDF

Info

Publication number: CA2654834A1
Authority: CA; Canada
Prior art keywords: stimulation; nerve; intensity; period; pattern
Prior art date: 2006-06-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002654834A

Other languages

English (en)

Inventor

John D. Dobak

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leptos Biomedical Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-09

Filing date

2007-06-11

Publication date

2007-12-21

2007-01-24 Priority claimed from US11/657,877 external-priority patent/US7702386B2/en

2007-06-11 Application filed by Individual filed Critical Individual

2007-12-21 Publication of CA2654834A1 publication Critical patent/CA2654834A1/fr

Status Abandoned legal-status Critical Current

Links

230000007383 nerve stimulation Effects 0.000 title description 23
210000005036 nerve Anatomy 0.000 claims abstract description 150
238000000034 method Methods 0.000 claims abstract description 102
241000124008 Mammalia Species 0.000 claims abstract description 32
230000004044 response Effects 0.000 claims abstract description 18
230000000638 stimulation Effects 0.000 claims description 658
210000002466 splanchnic nerve Anatomy 0.000 claims description 196
230000008859 change Effects 0.000 claims description 51
230000002889 sympathetic effect Effects 0.000 claims description 44
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 40
210000004369 blood Anatomy 0.000 claims description 33
239000008280 blood Substances 0.000 claims description 33
230000004936 stimulating effect Effects 0.000 claims description 23
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
239000008103 glucose Substances 0.000 claims description 21
102000004877 Insulin Human genes 0.000 claims description 20
108090001061 Insulin Proteins 0.000 claims description 20
229940125396 insulin Drugs 0.000 claims description 20
101800001586 Ghrelin Proteins 0.000 claims description 19
102000012004 Ghrelin Human genes 0.000 claims description 19
150000003943 catecholamines Chemical class 0.000 claims description 19
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 19
102000014777 Adipokines Human genes 0.000 claims description 13
108010078606 Adipokines Proteins 0.000 claims description 13
239000000478 adipokine Substances 0.000 claims description 13
210000001186 vagus nerve Anatomy 0.000 claims description 11
235000005686 eating Nutrition 0.000 claims description 8
230000004872 arterial blood pressure Effects 0.000 claims description 7
102000016267 Leptin Human genes 0.000 claims description 6
108010092277 Leptin Proteins 0.000 claims description 6
229940039781 leptin Drugs 0.000 claims description 6
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 6
210000005037 parasympathetic nerve Anatomy 0.000 claims description 4
230000004580 weight loss Effects 0.000 abstract description 36
230000001965 increasing effect Effects 0.000 description 90
238000011282 treatment Methods 0.000 description 73
230000004913 activation Effects 0.000 description 67
208000001145 Metabolic Syndrome Diseases 0.000 description 65
206010028347 Muscle twitching Diseases 0.000 description 65
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 64
230000037406 food intake Effects 0.000 description 63
235000012631 food intake Nutrition 0.000 description 63
208000008589 Obesity Diseases 0.000 description 52
235000020824 obesity Nutrition 0.000 description 52
238000002560 therapeutic procedure Methods 0.000 description 51
210000002569 neuron Anatomy 0.000 description 43
208000001072 type 2 diabetes mellitus Diseases 0.000 description 43
239000000835 fiber Substances 0.000 description 37
208000016261 weight loss Diseases 0.000 description 36
241000282465 Canis Species 0.000 description 33
230000007423 decrease Effects 0.000 description 30
230000002829 reductive effect Effects 0.000 description 29
210000001519 tissue Anatomy 0.000 description 29
230000003247 decreasing effect Effects 0.000 description 28
241001465754 Metazoa Species 0.000 description 25
238000005096 rolling process Methods 0.000 description 23
206010052804 Drug tolerance Diseases 0.000 description 21
230000026781 habituation Effects 0.000 description 21
210000003205 muscle Anatomy 0.000 description 21
206010020772 Hypertension Diseases 0.000 description 20
206010022489 Insulin Resistance Diseases 0.000 description 19
230000000694 effects Effects 0.000 description 19
230000009467 reduction Effects 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 18
210000002820 sympathetic nervous system Anatomy 0.000 description 18
108010010234 HDL Lipoproteins Proteins 0.000 description 17
102000015779 HDL Lipoproteins Human genes 0.000 description 17
238000012360 testing method Methods 0.000 description 16
230000036982 action potential Effects 0.000 description 13
210000004126 nerve fiber Anatomy 0.000 description 13
235000019627 satiety Nutrition 0.000 description 13
230000036186 satiety Effects 0.000 description 13
208000032928 Dyslipidaemia Diseases 0.000 description 12
208000017170 Lipid metabolism disease Diseases 0.000 description 12
210000002784 stomach Anatomy 0.000 description 12
102000007330 LDL Lipoproteins Human genes 0.000 description 11
108010007622 LDL Lipoproteins Proteins 0.000 description 11
230000036772 blood pressure Effects 0.000 description 11
210000001170 unmyelinated nerve fiber Anatomy 0.000 description 11
206010060378 Hyperinsulinaemia Diseases 0.000 description 10
230000003451 hyperinsulinaemic effect Effects 0.000 description 10
201000008980 hyperinsulinism Diseases 0.000 description 10
230000028327 secretion Effects 0.000 description 10
210000000579 abdominal fat Anatomy 0.000 description 9
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 9
210000000609 ganglia Anatomy 0.000 description 9
201000001421 hyperglycemia Diseases 0.000 description 9
230000001537 neural effect Effects 0.000 description 9
230000002459 sustained effect Effects 0.000 description 9
210000000331 sympathetic ganglia Anatomy 0.000 description 9
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 8
229930182837 (R)-adrenaline Natural products 0.000 description 8
210000001015 abdomen Anatomy 0.000 description 8
230000003213 activating effect Effects 0.000 description 8
210000000577 adipose tissue Anatomy 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
230000001351 cycling effect Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
229960005139 epinephrine Drugs 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
238000003860 storage Methods 0.000 description 8
210000000225 synapse Anatomy 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 7
230000003187 abdominal effect Effects 0.000 description 7
210000000593 adipose tissue white Anatomy 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
210000000944 nerve tissue Anatomy 0.000 description 7
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
235000019789 appetite Nutrition 0.000 description 6
230000036528 appetite Effects 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000037396 body weight Effects 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
229960002748 norepinephrine Drugs 0.000 description 6
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
206010000060 Abdominal distension Diseases 0.000 description 5
208000006011 Stroke Diseases 0.000 description 5
102100040247 Tumor necrosis factor Human genes 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
201000010099 disease Diseases 0.000 description 5
235000012054 meals Nutrition 0.000 description 5
208000010125 myocardial infarction Diseases 0.000 description 5
210000000496 pancreas Anatomy 0.000 description 5
230000001734 parasympathetic effect Effects 0.000 description 5
210000000578 peripheral nerve Anatomy 0.000 description 5
210000000278 spinal cord Anatomy 0.000 description 5
230000008700 sympathetic activation Effects 0.000 description 5
210000000115 thoracic cavity Anatomy 0.000 description 5
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
230000004584 weight gain Effects 0.000 description 5
235000019786 weight gain Nutrition 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 4
210000003766 afferent neuron Anatomy 0.000 description 4
230000000712 assembly Effects 0.000 description 4
238000000429 assembly Methods 0.000 description 4
210000003050 axon Anatomy 0.000 description 4
238000004891 communication Methods 0.000 description 4
230000008602 contraction Effects 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000000268 efferent neuron Anatomy 0.000 description 4
230000000763 evoking effect Effects 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
210000001596 intra-abdominal fat Anatomy 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000000653 nervous system Anatomy 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000008855 peristalsis Effects 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
230000011514 reflex Effects 0.000 description 4
238000004088 simulation Methods 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
208000032841 Bulimia Diseases 0.000 description 3
208000003098 Ganglion Cysts Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
238000008214 LDL Cholesterol Methods 0.000 description 3
208000028389 Nerve injury Diseases 0.000 description 3
208000005400 Synovial Cyst Diseases 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
210000003403 autonomic nervous system Anatomy 0.000 description 3
230000003376 axonal effect Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
235000021316 daily nutritional intake Nutrition 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
210000002249 digestive system Anatomy 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000002513 implantation Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
230000008764 nerve damage Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 3
230000008569 process Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
102000011690 Adiponectin Human genes 0.000 description 2
108010076365 Adiponectin Proteins 0.000 description 2
206010004716 Binge eating Diseases 0.000 description 2
206010059186 Early satiety Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
210000001943 adrenal medulla Anatomy 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
208000014679 binge eating disease Diseases 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
230000023852 carbohydrate metabolic process Effects 0.000 description 2
235000021256 carbohydrate metabolism Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000004020 conductor Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000011833 dog model Methods 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
230000005284 excitation Effects 0.000 description 2
210000002468 fat body Anatomy 0.000 description 2
235000019525 fullness Nutrition 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
230000036541 health Effects 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
208000002551 irritable bowel syndrome Diseases 0.000 description 2
210000001699 lower leg Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000037323 metabolic rate Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
230000023105 myelination Effects 0.000 description 2
230000008035 nerve activity Effects 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
210000001187 pylorus Anatomy 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000035807 sensation Effects 0.000 description 2
235000019615 sensations Nutrition 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052719 titanium Inorganic materials 0.000 description 2
239000010936 titanium Substances 0.000 description 2
230000007704 transition Effects 0.000 description 2
238000012800 visualization Methods 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
208000001762 Gastric Dilatation Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
206010020466 Hunger Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000031773 Insulin resistance syndrome Diseases 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
241000193803 Therea Species 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
210000003489 abdominal muscle Anatomy 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
210000004960 anterior grey column Anatomy 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
210000000467 autonomic pathway Anatomy 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
235000019787 caloric expenditure Nutrition 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
239000003990 capacitor Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000021373 diet component Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000001916 dieting Nutrition 0.000 description 1
230000037228 dieting effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
230000010339 dilation Effects 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000005672 electromagnetic field Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
238000004146 energy storage Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002594 fluoroscopy Methods 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
230000002102 hyperpolarization Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000009413 insulation Methods 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
210000000876 intercostal muscle Anatomy 0.000 description 1
210000001937 intercostal nerve Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003666 myelinated nerve fiber Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
229960001243 orlistat Drugs 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
-1 percentage of lean Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
235000017924 poor diet Nutrition 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000004686 stellate ganglion Anatomy 0.000 description 1
210000001321 subclavian vein Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000005641 tunneling Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000001515 vagal effect Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000004260 weight control Methods 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Developmental Disabilities (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Child & Adolescent Psychology (AREA)
Electrotherapy Devices (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

CA002654834A 2006-06-09 2007-06-11 Stimulation nerveuse dynamique employant une modulation de frequence Abandoned CA2654834A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US80441506P	2006-06-09	2006-06-09
US60/804,415		2006-06-09
US11/657,877		2007-01-24
US11/657,877 US7702386B2 (en)	2002-03-22	2007-01-24	Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
PCT/US2007/013780 WO2007146287A2 (fr)	2006-06-09	2007-06-11	Stimulation nerveuse dynamique employant une modulation de fréquence

Publications (1)

Publication Number	Publication Date
CA2654834A1 true CA2654834A1 (fr)	2007-12-21

Family

ID=38832487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002654834A Abandoned CA2654834A1 (fr)	2006-06-09	2007-06-11	Stimulation nerveuse dynamique employant une modulation de frequence

Country Status (3)

Country	Link
EP (1)	EP2106275A2 (fr)
CA (1)	CA2654834A1 (fr)
WO (1)	WO2007146287A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7689276B2 (en)	2002-09-13	2010-03-30	Leptos Biomedical, Inc.	Dynamic nerve stimulation for treatment of disorders
US7702386B2 (en)	2002-03-22	2010-04-20	Leptos Biomedical, Inc.	Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US7689277B2 (en)	2002-03-22	2010-03-30	Leptos Biomedical, Inc.	Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7239912B2 (en)	2002-03-22	2007-07-03	Leptos Biomedical, Inc.	Electric modulation of sympathetic nervous system
WO2010011969A1 (fr)	2008-07-24	2010-01-28	Boston Scientific Neuromodulation Corporation	Système et procédé pour éviter, inverser, et gérer l'adaptation neurologique à une stimulation électrique
US8321030B2 (en)	2009-04-20	2012-11-27	Advanced Neuromodulation Systems, Inc.	Esophageal activity modulated obesity therapy
US8788048B2 (en) *	2010-11-11	2014-07-22	Spr Therapeutics, Llc	Systems and methods for the treatment of pain through neural fiber stimulation
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5188104A (en) *	1991-02-01	1993-02-23	Cyberonics, Inc.	Treatment of eating disorders by nerve stimulation
US5458626A (en) *	1993-12-27	1995-10-17	Krause; Horst E.	Method of electrical nerve stimulation for acceleration of tissue healing
US6542776B1 (en) *	1999-04-14	2003-04-01	Transneuronix Inc.	Gastric stimulator apparatus and method for installing

2007
- 2007-06-11 EP EP07809483A patent/EP2106275A2/fr not_active Withdrawn
- 2007-06-11 CA CA002654834A patent/CA2654834A1/fr not_active Abandoned
- 2007-06-11 WO PCT/US2007/013780 patent/WO2007146287A2/fr active Search and Examination

Also Published As

Publication number	Publication date
WO2007146287A2 (fr)	2007-12-21
EP2106275A2 (fr)	2009-10-07
WO2007146287A3 (fr)	2009-04-02

Publication	Publication Date	Title
US7937145B2 (en)	2011-05-03	Dynamic nerve stimulation employing frequency modulation
US7689277B2 (en)	2010-03-30	Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7702386B2 (en)	2010-04-20	Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US20090118777A1 (en)	2009-05-07	Efferent and afferent splanchnic nerve stimulation
US7689276B2 (en)	2010-03-30	Dynamic nerve stimulation for treatment of disorders
US8295926B2 (en)	2012-10-23	Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US7551964B2 (en)	2009-06-23	Splanchnic nerve stimulation for treatment of obesity
US8321030B2 (en)	2012-11-27	Esophageal activity modulated obesity therapy
US7236822B2 (en)	2007-06-26	Wireless electric modulation of sympathetic nervous system
US7239912B2 (en)	2007-07-03	Electric modulation of sympathetic nervous system
US20100168820A1 (en)	2010-07-01	Automatic threshold assesment utilizing patient feedback
US20080262411A1 (en)	2008-10-23	Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US20120053660A1 (en)	2012-03-01	Splanchnic nerve stimulation for treatment of obesity
AU2010201688A1 (en)	2010-05-20	Splanchnic nerve stimulation for treatment of obesity
CA2654834A1 (fr)	2007-12-21	Stimulation nerveuse dynamique employant une modulation de frequence

Legal Events

Date	Code	Title	Description
2013-08-06	FZDE	Dead	Effective date: 20130611